Blastic Plasmacytoid Dendritic Cell Neoplasm Presenting as Erythematous Nodules with Gallbladder Involvement
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Dear Editor: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, highly aggressive hematopoietic malignancy which is derived from the precursors of plasmacytoid dendritic cells 1 A previously healthy 43-year-old woman presented with 3-week history of nodular eruptions on the face. She had no systemic symptoms. Physical examination did not reveal any abnormalities, except for the skin lesions. Skin examination revealed multiple various-sized erythematous plaques and nodules on the face (Fig. 1) . We obtained informed consent for using the photos from the patient. Histopathologic findings showed a diffuse cellular infiltrate in the entire dermis ( Fig. 2A) . The cells were monomorphic medium sized atypical lymphocytes containing irregular round or indented nuclei with pale cytoplasm (Fig. 2B ). Immunohistochemical stains were positive for CD4 ( Fig. 2C) 4 . In majority of cases, skin is affected at the initial presentation as bruise-like tumefaction or an erythematous nodule 1, 5 . BPDCN is often accompanied by extracutaneous involvement, including bone marrow, lymph node, and peripheral blood but practically any organ can be affected 1 . Our patient presented with multiple erythematous nodules on the face, which is a rare pattern in BPDCN to the best of our knowledge 1, 5 . After review of the literature, we believe that the GB involvement described herein has not been documented before. Pathologic evaluation and immunophenotyping play an important role in the diagnosis of BPDCN, which are char- acterized by a diffuse monomorphic infiltrate of medium-sized plasmacytoid cells and the expression of CD4, CD56, and CD123 in the absence of CD3, CD20, or myeloperoxidase 3, 4 .
The clinical course of BPDCN is aggressive with a median survival of 12∼14 months 1, 5 . However, there is no standardized therapeutic strategy. High-dose chemotherapy followed by allogeneic stem cell transplantation can provide durable disease control like our patient 1 . Several factors, including relatively young age and undergoing stem cell transplantation may contribute to more favorable prognosis in this case.
In conclusion, BPDCN may demonstrate various clinical presentations, which could be quite confusing for the dermatologist to diagnose. Thus histopathologic evaluation of skin biopsy is important to confirm diagnosis. We believe that this case demonstrates a rare cutaneous and extracutaneous presentation of BPDCN and emphasizes the importance of being aware of this rare disease in order to provide effective treatment.
